Schoen Klinik Vogtareuth SE & Co. KG

The medical center is at the forefront of epilepsy research, focusing on innovative therapies for rare forms such as Myoclonic Astatic Epilepsy (Doose-Syndrome). The center's ongoing studies aim to enhance the understanding of this condition and improve patient outcomes through advanced treatment options.

• Myoclonic Astatic Epilepsy (Doose-Syndrome)
• Long-term safety monitoring
• Fenfluramine as add-on therapy

By exploring the long-term safety and efficacy of Fenfluramine as an adjunctive treatment, the center contributes significantly to the development of safer and more effective therapeutic strategies for epilepsy patients.

Specializing in CDKL5 Deficiency Disorder (CDD), the medical center is dedicated to advancing treatment options for this challenging condition. Through rigorous clinical trials, the center evaluates the efficacy and safety of novel therapies, aiming to improve the quality of life for affected individuals.

• CDKL5 Deficiency Disorder (CDD)
• Efficacy of Fenfluramine (ZX008)
• Long-term safety and tolerability

The center's research on Fenfluramine as an adjunctive therapy provides critical insights into its potential benefits and risks, paving the way for more effective management of CDD.